CD73: a potential biomarker for anti-PD-1 therapy

Paul A Beavis, Clare Y Slaney, Nicole Milenkovski, Melissa A Henderson, Sherene Loi, John Stagg, Michael H Kershaw, Phillip K Darcy

Research output: Contribution to journalComment / DebateResearchpeer-review

16 Citations (Scopus)

Abstract

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson s Disease, this combination warrants further investigation. ? 2015, Taylor Francis Group, LLC
Original languageEnglish
Pages (from-to)1 - 3
Number of pages3
JournalOncoImmunology
Volume4
Issue number11
DOIs
Publication statusPublished - 2015

Cite this

Beavis, P. A., Slaney, C. Y., Milenkovski, N., Henderson, M. A., Loi, S., Stagg, J., ... Darcy, P. K. (2015). CD73: a potential biomarker for anti-PD-1 therapy. OncoImmunology, 4(11), 1 - 3. https://doi.org/10.1080/2162402X.2015.1046675
Beavis, Paul A ; Slaney, Clare Y ; Milenkovski, Nicole ; Henderson, Melissa A ; Loi, Sherene ; Stagg, John ; Kershaw, Michael H ; Darcy, Phillip K. / CD73: a potential biomarker for anti-PD-1 therapy. In: OncoImmunology. 2015 ; Vol. 4, No. 11. pp. 1 - 3.
@article{bfbc51b7ee2a4903b7b135baad1059cb,
title = "CD73: a potential biomarker for anti-PD-1 therapy",
abstract = "In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson s Disease, this combination warrants further investigation. ? 2015, Taylor Francis Group, LLC",
author = "Beavis, {Paul A} and Slaney, {Clare Y} and Nicole Milenkovski and Henderson, {Melissa A} and Sherene Loi and John Stagg and Kershaw, {Michael H} and Darcy, {Phillip K}",
year = "2015",
doi = "10.1080/2162402X.2015.1046675",
language = "English",
volume = "4",
pages = "1 -- 3",
journal = "OncoImmunology",
issn = "2162-402X",
publisher = "Taylor & Francis",
number = "11",

}

Beavis, PA, Slaney, CY, Milenkovski, N, Henderson, MA, Loi, S, Stagg, J, Kershaw, MH & Darcy, PK 2015, 'CD73: a potential biomarker for anti-PD-1 therapy', OncoImmunology, vol. 4, no. 11, pp. 1 - 3. https://doi.org/10.1080/2162402X.2015.1046675

CD73: a potential biomarker for anti-PD-1 therapy. / Beavis, Paul A; Slaney, Clare Y; Milenkovski, Nicole; Henderson, Melissa A; Loi, Sherene; Stagg, John; Kershaw, Michael H; Darcy, Phillip K.

In: OncoImmunology, Vol. 4, No. 11, 2015, p. 1 - 3.

Research output: Contribution to journalComment / DebateResearchpeer-review

TY - JOUR

T1 - CD73: a potential biomarker for anti-PD-1 therapy

AU - Beavis, Paul A

AU - Slaney, Clare Y

AU - Milenkovski, Nicole

AU - Henderson, Melissa A

AU - Loi, Sherene

AU - Stagg, John

AU - Kershaw, Michael H

AU - Darcy, Phillip K

PY - 2015

Y1 - 2015

N2 - In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson s Disease, this combination warrants further investigation. ? 2015, Taylor Francis Group, LLC

AB - In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson s Disease, this combination warrants further investigation. ? 2015, Taylor Francis Group, LLC

UR - http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1046675

U2 - 10.1080/2162402X.2015.1046675

DO - 10.1080/2162402X.2015.1046675

M3 - Comment / Debate

VL - 4

SP - 1

EP - 3

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-402X

IS - 11

ER -

Beavis PA, Slaney CY, Milenkovski N, Henderson MA, Loi S, Stagg J et al. CD73: a potential biomarker for anti-PD-1 therapy. OncoImmunology. 2015;4(11):1 - 3. https://doi.org/10.1080/2162402X.2015.1046675